LogicBio Therapeutics Inc

LogicBio Therapeutics — Investor Presentation (January 2021)

43 slides from LogicBio Therapeutics's investor presentation, Jan 12, 2021

  1. Slide 1: Delivering differentiated genomic medicines to transform the lives of patients

    Delivering differentiated genomic medicines to transform the lives of patients suffering from devastating diseases January 2021 Exhibit 99.1

  2. Slide 2: Forward-looking statements

    Forward-looking statements This presentation contains “forward-looking statements” within the meaning of the federal securities laws. These forward-looking statements are not statements of historical facts and are based on management’s beliefs and assumptions and on information currently available t

  3. Slide 3: LogicBio overview

    Clinical stage genomic medicine company aiming to deliver transformational therapies to patients with high unmet needs LogicBio overview Differentiated gene editing platform to provide a durable treatment through precise gene insertion Open IND for MMA program with initial clinical proof of concept

  4. Slide 4: GeneRide: a differentiated gene editing platform

    GeneRide™ : a differentiated gene editing platform Nuclease free leveraging homologous recombination Durable therapeutic transgene expression driven by endogenous promoters Site-specific integration Modular and broadly applicable Next-Gen AAV capsid platform Tissue tropism assessed in clinically pre

  5. Slide 5: Leveraging initial PoCs to expand the company's pipeline

    Leveraging initial PoCs to expand the company’s pipeline LogicBio overview Intracellular Proteins Ex Vivo Undisclosed Tissues Secreted Proteins HEM B A1ATD PoC Color code Early data Planned MMA Crigler-Najjar Undisclosed Undisclosed Undisclosed Undisclosed Clinical stage Indication selection criteri

  6. Slide 6: 2020 Key Accomplishments

    Critical advancements across pipeline and platform 2020 Key Accomplishments LogicBio overview Pipeline Platform ✓ IND cleared for LB-001 in pediatric MMA patients In-vivo gene editing technology Systemic delivery Infants and children ✓ Initiated LB-301 research collaboration with Takeda (Crigler-Naj

  7. Slide 7: Initiating FIH clinical trial and building on two platforms

    Initiating FIH clinical trial and building on our two innovative proprietary platforms Expected 2021 Milestones LogicBio overview Clinical study Platform Enroll first patient in SUNRISE trial Communicate operational updates for SUNRISE trial Present interim clinical safety and efficacy data Expand t

  8. Slide 8: GeneRide Platform

    GeneRide™ Platform Logicbio

  9. Slide 9: GeneRide: promoterless, nuclease-free gene editing platform

    GeneRide™: promoterless, nuclease-free gene editing platform GeneRide platform Targeted cell entry Traffic to nucleus Site-specific recognition Homologous recombination driven integration Transcription of fused mRNA Polycistronic protein expression

  10. Slide 10: Taking a ride on albumin for liver-directed indications

    Taking a ride on albumin for liver-directed indications GeneRide™ enables therapeutic protein expression levels GeneRide platform Most abundant protein in circulation and the most highly expressed gene in the liver Transcriptional profiling data from The GTEx Project ALB – Albumin PAH – phenylalanin

  11. Slide 11: LB-001: Clinical Stage Pediatric Patients with MMA

    GeneRide™ Platform LB-001: Clinical Stage Pediatric Patients with MMA

  12. Slide 12: Methylmalonic acidemia (MMA)

    Life-threatening inborn error of metabolism with no pharmacologic treatment options Methylmalonic acidemia (MMA) LB-001 program for pediatric patients with MMA Epidemiology and Etiology: US Incidence: 1 in 50,000 births US Prevalence: 1,000 – 1,500 On the newborn screening panel in every US state Or

  13. Slide 13: LB-001 program for pediatric patients with MMA

    LB-001 program for pediatric patients with MMA Liver transplantation in young patients improves metabolic stability but may be accompanied by significant morbidity and is not readily accessible Finite number of liver donors Significant risks associated with surgery High procedural costs Lifetime dep

  14. Slide 14: LogicBio

    LogicBio

  15. Slide 15: LB-001 protects MMA mice

    LB-001 program for pediatric patients with MMA Adult mice dosed at 5 × 1013 vg/kg Ko et al., ASGCT, 2020. LB-001 improved survival LB-001 improved growth LB-001 prevented elevations in circulating MMA LP SP HP PERCENT SURVIVAL AGE (MONTHS) Treated (n = 7) Vehicle (n = 7) p=0.052, log rank test BODY

  16. Slide 16: mLB-001 delivers selective advantage to corrected hepatocytes

    LB-001 program for pediatric patients with MMA In diseased MMA mice selective advantage was observed in GeneRide corrected, Mmut expressing hepatocytes, which expanded over time leading to increase levels of circulating biomarker ALB-2A Ko et al., ASGCT, 2020. Derived from Drouin et al., ASGCT, 2020

  17. Slide 17: Expansion of GeneRide corrected hepatocytes correlates with biomarker and endpoint

    Expansion of GeneRide corrected hepatocytes reveals correlation between PD, disease biomarker, clinical endpoint LB-001 program for pediatric patients with MMA Increased PD biomarker correlated with reduction of disease biomarker and improvement in clinically relevant endpoint MMA (mM) BODYWEIGHT (g

  18. Slide 18: SUNRISE trial design

    One-time treatment, 52-week trial, followed by roll-over to long-term follow-up trial 8 patients across 6 US sites Two cohorts planned with parallel dose escalation and intracohort age de-escalation Open-label, phase 1/2 trial of LB-001 in pediatric MMA patients SUNRISE trial design LB-001 program f

  19. Slide 19: SUNRISE trial design

    SUNRISE tria LB-001 program for pediatric patients with MMA SUNRISE trial design Prophylactic corticosteroid regimen to mitigate potential cellular immune responses 6-week staggering interval between each patient Primary objective: Assess the safety and tolerability of LB-001 Secondary objectives: A

  20. Slide 20: Anticipated milestones and guidance

    Early 2021 – First patient to be dosed Mid-2021 – Retrospective natural history data expected to be made available Mid-2021 – Update on enrollment, dose escalation, and age de-escalation Late 2021 – Interim proof of concept data expected to be made available Anticipated milestones and guidance Fulso

  21. Slide 21: LB-301: Preclinical Stage Pediatric Patients with CN

    Joint development GeneRide™ Platform LB-301: Preclinical Stage Pediatric Patients with CN

  22. Slide 22: Crigler-Najjar Syndrome (CN)

    Life-threatening inborn error of metabolism with no treatment options Crigler-Najjar Syndrome (CN) LB-301 program Incidence: 1 in 1,000,000 births (Global) Prevalence: 400 – 1,200 (Global) 100 – 300 (US) Hyperbilirubinemia caused by mutations in UGT1A1 gene Results in reduction or lack of bilirubin

  23. Slide 23: GeneRide rescued neonatal Crigler-Najjar mice

    LB-301 program GeneRide™ rescued neonatal Crigler-Najjar mice and reduced clinically relevant circulating biomarker Ko et al., ASGCT, 2020. Total Bilirubin Survival Rate *** p<0.001 **** p<0.0001

  24. Slide 24: Next-Gen Capsid Platform

    Next-Gen Capsid Platform Logicbio

  25. Slide 25: Next generation capsids developed to target human hepatocytes

    LogicBio next generation capsids developed to target human hepatocytes Natural AAVs show variable potency across species Next-gen capsid platform Sponsor DC Transgene Capsid Serotype Mouse NHP Human Dose (vg/kg) Peak expression levels Dose (vg/kg) Peak expression levels Dose (vg/kg) Peak expression

  26. Slide 26: Developing capsids for highly effective gene therapy products

    Developing capsids for highly effective gene therapy products Next-gen capsid platform Therapeutic Level EXPRESSION Low dose: 10 commonly accepted sustainable dose for liver disease patients in clinical trials 12 vg/kg < $10K Low COGS per patient (estimation) Specific Tissue Tropism High Potency Add

  27. Slide 27: A 3-step platform enhancing 4 key AAV properties

    Manufacturability Low Immunogenicity Specific Tissue Tropism Functional Transduction A 3-step platform enhancing all 4 AAV’s key properties Next-gen capsid platform Novel AAV Design: Selection of novel AAV: Process Development: Enhanced Properties: 1 2 3

  28. Slide 28: An evolutive and iterative development platform

    An evolutive and iterative ‘tech-sAAVy’ development platform Next-gen capsid platform Selection Novel AAV design Next-Gen PLATFORM 1 Process Development 3 2 Technologies of our multi-pronged approach are constantly evolving & updated Each generation of Next-Gen capsid helps design the next one based

  29. Slide 29: Designing massive and highly variable AAV libraries

    Designing massive and highly variable AAV libraries with CMRI state-of-the-art bioengineering technologies Next-gen capsid platform DIRECTED EVOLUTION Library creation using: • In silico design • Machine learning • Enhanced DNA shuffling enhanced through sequence optimization • EP-PCR mutagenesis •

  30. Slide 30: AAV selection and assessment in clinically predictive models

    AAV selection & assessment in clinically predictive models Next-gen capsid platform SELECTION ASSESSMENT ~10⁷ variants / library Tissue Tropism Manufacturability • Selective pressure with tissue relevant models • Screening for high yields Functional Expression Low Immunogenicity • Confirmatory studie

  31. Slide 31: Assessing capsid manufacturability through GMP-like process

    Assessing capsid manufacturability through GMP-like process Next-gen capsid platform Capsid manufacturing yields assessed in PoC bioreactors scaling down GMP process designed to allow an early COGs projection AmBr 250ml Modular Single use STR 50L Confirmatory assays scaled up to 50L and modeling indu

  32. Slide 32: LK03: initial clinical validation

    33 LK03: initial clinical validation Next-gen capsid platform Technologies used to identify LK03 were enhanced in our Next-Gen discovery platform Optimized to target human hepatocytes: ~30x more potent than AAV5 in ongoing Hemophilia A clinical trials1 Preexisting neutralizing antibodies rate of 23%

  33. Slide 33: Next-Gen platform improves LK03

    Next-Gen platform improves LK03 on original engine development Next-gen capsid platform LK03 AAV-LBX Library creation shuffling sequences of 10 serotypes Xenograft humanized mice with low human hepatocyte repopulation In vitro transduction assessment Library creation using 2 more serotype variants E

  34. Slide 34: AAV-LBX demonstrates improved functional transduction

    Xenograft humanized mice are treated with capsids with different barcodes corresponding to different doses Plotting RNA (expression) against DNA (transduction) allows for the calculation of expression rates A steeper slope indicates a capsid has enhanced functional transduction properties AAV-LBX de

  35. Slide 35: AAV-LBX displays improved immunological profile vs. LK03

    AAV-LBX display improved immunological profile vs. LK03 AAV-LBX was tested for IVIG neutralization in HuH-7 cells in vitro Transduction efficiency was normalized to no-IVIG control (DMEM) AAV-LBX display less neutralization by IVIG than AAV-LK03 1_1 100.0 1_2 1_4 1_8 1_16 1_32 LK03 DMEM Dilution AAV

  36. Slide 36: AAV-LBX: Best performer in NHP with FIX as reporter gene

    AAV-LBX : Best performer in NHP with FIX as reporter gene Next-gen capsid platform AAV-LBX LK03 AAV8 c 600 Factor IX (ng/mL) 400 200 0 AAV-LBX was evaluated in NHP with hFIX as a reporter Compared to LK03 (the most potent liver-targeted clinical capsid), AAV-LBX encapsidated cassette led to 4x highe

  37. Slide 37: AAV-LBX shows outstanding production yields

    AAV-LBX shows outstanding production yields using LogicBio’s proprietary process Next-gen capsid platform * Published data, reviewed by Merten, 2016 – yield assessed by quantitative Polymerase Chain Reaction (qPCR) 0E+00 1E+14 2E+14 3E+14 4E+14 5E+14 6E+14 Titer in crude harvest (vg/L) AAV yield in

  38. Slide 38: AAV-LBX reaching LogicBio's objective gene therapy TPP

    38 Next-gen capsid platform AAV-LBX reaching LogicBio’s objective gene therapy TPP Improved functional Improved transduction of immunological human hepatocytes profile vs. LKO3 High manufacturing yields vs. published competition data Best performer in NHP- with FIX as a reporter vs. LKO3 Low dose: i

  39. Slide 39: LogicBio corporate overview

    LogicBio corporate overview

  40. Slide 40: Experienced leadership team

    Fred Chereau President and Chief Executive Officer Cecilia Jones Chief Financial Officer Daniel Gruskin, M.D. SVP, Head of Clinical Development Kyle Chiang, Ph.D. Chief Operating Officer Nelson Chau, Ph.D. VP, Biology & Translational Research Matthias Hebben, Ph.D. Global VP, Head of Technology Deve

  41. Slide 41: Pipeline focusing on severe genetic diseases

    LogicBio corporate overview DISCOVERY POC IND ENABLING PHASE I/II PHASE III MMA Crigler-Najjar undisclosed HEM B A1ATD undisclosed additional tissues CLINIAL intracellular secreted Exciting pipeline focusing on severe genetic diseases

  42. Slide 42: Initiating FIH clinical trial and building on two platforms

    Initiating FIH clinical trial and building on our two innovative proprietary platforms Expected 2021 Milestones LogicBio corporate overview Clinical study Platform Enroll first patient in SUNRISE trial Communicate operational updates for SUNRISE trial Present interim clinical safety and efficacy dat

  43. Slide 43: LogicBio Therapeutics

    LogicBio THERAPEUTICS RIDE smart - fast -together- FOR PATIENTS

LogicBio Therapeutics — Investor Presentation (January 2021) on 6ix